BioSpace News Archive

Drug Development

RegeneRx Eyes Pipeline Shuffle in Light of Development Delays

In a letter to shareholders, RegeneRx provided a pipeline update for investors Monday, outlining plans to potentially move forward with a new asset in light of development delays.

August 22, 2022
·
3 min read
·
Mark Terry
Gilead Scores First Approval for Twice-Yearly HIV Drug in Latest Advance

Gilead’s regulatory win could open the doors for patients with complicated medication histories and for whom viral suppression regimens have become difficult to create.

August 22, 2022
·
2 min read
·
Tristan Manalac
Business

Innovation Hubs are Driving Economic Growth Across the US

Across the United States, Clusters of innovation have created self-sustaining ecosystems that are shaping the future of the life sciences industry - and driving economic growth.

August 22, 2022
·
5 min read
·
Alex Keown
Monkeypox Testing Market Size, Share, Growth, Forecast Report 2022 to 2030

Monkeypox is a viral zoonotic disease caused by the monkeypox virus, a member of the orthropox genus in the family poxviridae.

August 22, 2022
·
2 min read
Drug Development

FDA Instructs Pfizer to Test Second Course of Paxlovid

Pfizer is to report initial data from a randomized trial of the second course of therapy of paxlovid in COVID-19 rebound patients by Sept. 2023.

August 22, 2022
·
2 min read
·
Mark Terry
Drug Development

Tessa Taps Ex-Takeda Exec to Propel CAR-T Assets Foward

Tessa Therapeutics has tapped former Takeda executive Thomas Willemsen as the man to take its CAR-T portfolio forward.

August 22, 2022
·
2 min read
·
Chris Moore
Business

Vaderis Forms to Tackle Vascular Malformations with Novartis Vet at the Helm

With financial backing from Medicxi, Vaderis Therapeutics AG emerged from stealth mode Monday with a focus on allosteric AKT inhibitors and a clinic-ready drug candidate.

August 22, 2022
·
2 min read
·
Alex Keown
Biotech Bay

180 Life Sciences with the University of Oxford Announce the Enrollment of the First Patient in a Trial of Anti-TNF for People with Early-Stage Frozen Shoulder

180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company announced that the first patient has been randomized in the clinical trial to evaluate anti-tumor necrosis factor (TNF) for patients with early-stage, pain predominant frozen shoulder.

August 22, 2022
·
10 min read
TC BioPharm to Present at the H.C. Wainwright 24th Annual Global Investment Conference

TC Biopharm today announced that Chief Executive Officer, Bryan Kobel will present a company overview at the H.C. Wainwright 24th annual global investment conference.

August 22, 2022
·
2 min read
Biotech Beach

Prominent Neurosurgeon Joins Leucadia Therapeutics as Company’s Founding Global Chief Medical Officer

Leucadia Therapeutics, a company working to cure Alzheimer’s disease, has hired a global chief medical officer practiced in skull base neurosurgery needed to implant the company’s revolutionary Arethusta® device, which drains disease-causing toxins from the brain.

August 22, 2022
·
3 min read